• Guided Therapeutics enrolled over 250 of 800 women targeted for its LuViva cervical cancer screening study with Türkiye’s Health Ministry.
• The ministry-funded study supports Türkiye’s plan to use the device to screen up to 20 million women annually.
• CEO Mark Faupel reported early indications that the study is progressing well, with enrollment expected to finish within the next few months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104162438) on November 04, 2026, and is solely responsible for the information contained therein.